Skip to main content

Table 4 Decrease in HbA1c in response to GLP-1 M based on subject features

From: Predicting responsiveness to GLP-1 pathway drugs using real-world data

Features

 

Number of subjects

Decrease in HbA1c

(mean ± SD)

False Discovery Rate (FDR)

Sex

Female

3911

0.45 ± 1.48

3.09E-02

Male

3945

0.55 ± 1.64

Hispanic ethnicity

No

7635

0.50 ± 1.56

2.39E-01

Yes

221

0.46 ± 1.58

Race

Africa American

1386

0.55 ± 1.83

8.91E-02

Non-African American

6470

0.48 ± 1.50

White

6193

0.49 ± 1.51

1.56E-01

Non-White

1663

0.53 ± 1.75

Asian

149

0.19 ± 1.08

1.06E-02

Non-Asian

7707

0.50 ± 1.58

Other

147

0.61 ± 1.34

9.96E-02

Non-Other

7709

0.49 ± 1.57

Chronic kidney disease

Yes

1069

0.32 ± 1.50

6.65E-04

No

6787

0.53 ± 1.58

Cardiomyopathy

Yes

341

0.32 ± 1.44

3.19E-02

No

7515

0.51 ± 1.57

Heart failure

Yes

654

0.33 ± 1.51

4.58E-03

No

7202

0.51 ± 1.57

Hypertension

Yes

5566

0.51 ± 1.51

3.59E-03

No

2290

0.47 ± 1.69

Arthritis

Yes

1447

0.45 ± 1.36

2.30E-01

No

6409

0.51 ± 1.61

Gastric bypass

Yes

148

0.64 ± 1.49

5.61E-02

No

7708

0.49 ± 1.57

Bowel resection

Yes

82

0.25 ± 1.55

2.23E-01

No

7774

0.50 ± 1.57

Retinopathy

Yes

333

0.28 ± 1.49

3.96E-02

No

7523

0.51 ± 1.57

Insulin

Yes

2031

0.66 ± 1.81

 < 1.0E-100

No

5825

0.44 ± 1.47

Metformin

Yes

4734

0.54 ± 1.59

1.78E-08

No

3122

0.43 ± 1.52

Sulfonylureas

Yes

3041

0.49 ± 1.58

5.16E-03

No

4815

0.50 ± 1.56

Thiazolidinediones

Yes

773

0.37 ± 1.53

3.29E-01

No

7083

0.51 ± 1.57

NSAIDs

Yes

3966

0.46 ± 1.53

5.16E-03

No

3890

0.54 ± 1.60

Painkiller

Yes

1542

0.43 ± 1.56

6.76E-03

No

6314

0.51 ± 1.57

Other T2D Medication

Yes

488

0.49 ± 1.38

6.08E-02

No

7368

0.50 ± 1.58

Smoking

Yes

2888

0.53 ± 1.59

2.82E-01

No

4968

0.48 ± 1.55

  1. Comparison of features of GLP-1M responders versus non-responders. Significant values are shown in bold in the right hand column